Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 5 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs BI 690517 (Primary) ; Eplerenone
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 18 Oct 2017 Status changed from not yet recruiting to recruiting.
- 04 Oct 2017 Planned initiation date changed from 20 Sep 2017 to 5 Oct 2017.
- 18 Sep 2017 Planned initiation date changed from 8 Sep 2017 to 20 Sep 2017.